Aurobindo Pharma Limited (AUROPHARMA)

Loading page…

Aurobindo Pharma Limited (AUROPHARMA) · mywealthgrid

About

Aurobindo Pharma manufactures and markets pharmaceutical formulations, operating at scale with a consolidated revenue run-rate of ₹9,150 Cr (Jun 2026 quarter). The company maintains 51.88% promoter control and operates with a 20%+ operating margin, positioning it as a mid-cap player in India's generics-dominated pharma sector.

Founded: 1986
Face value: ₹1

Market cap

₹97,389 Cr

P/E

26.2×

P/B

2.6×

Dividend yield

0.2%

ROE

9.9%

ROCE

14.7%

Debt / equity

0.2

OPM

20.3%

EPS (TTM)

₹63.9

Book value

₹652.4

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

ROE of 9.94% suggests capital is not generating competitive returns relative to typical pharma benchmarks — verify if this reflects transitional investments or structural capital efficiency issues.
Consolidated operating margin of 19.8–20.56% over recent quarters leaves limited buffer against input-cost inflation or pricing pressure — verify vulnerability to commodity or FX shocks.
PE of 25.38 implies market is pricing in growth; a miss on revenue or earnings would correct sharply, especially given 1y rally of 51.65% from lower base.
Standalone quarterly revenue flat at ₹2,750–₹2,800 Cr despite consolidated growth — verify whether standalone segment is mature or facing headwinds.

Generated analysis · source review pending

Growth drivers

Consolidated revenue grew from ₹8,285.7 Cr (Sep 2025) to ₹9,150.35 Cr (Jun 2026) — verify whether this ~10% growth trajectory is sustained in coming quarters.
Standalone operating margin reached 31.51% in Jun 2026, above the recent 25–30% range; if this spread to consolidated operations, profit growth would exceed revenue growth — verify drivers and repeatability.
Buyback announced Apr 2026 reduces share count, generating EPS accretion independent of revenue growth — verify amount and timeline.
Recent dividend and buyback activity indicates strong free cash flow generation — verify if this scales with revenue growth or if reinvestment in capacity is constrained.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹1,676.8-1.2%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 20.3%
+Comfortable interest coverage of 14.5×

Cons

−Low return on equity of 10.8% (3-yr avg)
−Profit declined 8.1% a year over the last 5 years
−Modest revenue growth of 6.3% a year over the last 5 years
−Low dividend payout of 6.3% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

63/100

Business quality: 58
Growth: 68
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY MIDCAP 50 NIFTY MIDCAP 150 NIFTY 200 NIFTY MIDSMALLCAP 400 NIFTY 500

Screen this industry

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	15,090	16,500	19,564	23,099	24,775	23,455	24,855	29,002	31,724	33,653
COGS	6,434	6,753	8,713	9,735	9,902	10,140	11,293	12,603	13,026	13,488
Gross profit	8,656	9,747	10,851	13,363	14,872	13,315	13,562	16,399	18,697	20,165
	5,221	5,972	6,899	8,554	9,594	8,960	9,855	10,573	12,146	13,317
	3,434	3,775	3,952	4,809	5,278	4,356	3,707	5,826	6,551	6,847
OPM %	22.8%	22.9%	20.2%	20.8%	21.3%	18.6%	14.9%	20.1%	20.7%	20.4%
Depreciation	428	558	668	967	1,055	1,127	1,245	1,522	1,649	1,778
Interest	67	78	263	160	74	49	140	290	457	384
	116	102	155	60	3,195	192	291	366	622	427
Profit before tax	—	3,241	—	3,743	7,344	3,373	2,613	4,380	5,066	5,112
Tax	760	818	727	914	2,010	726	685	1,211	1,583	1,609
Tax %	—	25.3%	—	24.4%	27.4%	21.5%	26.2%	27.7%	31.2%	31.5%
	2,302	2,423	2,365	2,830	5,334	2,647	1,928	3,169	3,484	3,503
PAT margin %	15.3%	14.7%	12.1%	12.3%	21.5%	11.3%	7.8%	10.9%	11%	10.4%
EPS (₹)	—	41.4	—	48.3	91	45.2	32.9	54.2	59.8	60.3
EPS adjusted (₹)	39.3	41.4	40.3	48.3	91.1	45.2	32.9	54.2	60	60.3
	—	9.1%	—	6.2%	4.4%	10%	22.8%	8.3%	0%	—
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	59	59	59	59	59	59	59	59	58	58
Reserves	9,313	11,622	13,832	—	21,871	24,517	26,781	29,784	32,595	37,833
Minority interest	2	2	2	—	—	—	12	8	—	—
	3,084	4,483	6,753	—	4,972	2,373	4,862	6,315	7,942	7,676
	3,791	4,936	5,809	—	6,952	6,973	8,177	8,905	9,190	12,935
Total equity & liabilities	16,249	21,101	26,454	—	33,854	33,922	39,890	45,072	49,785	58,502
	4,834	6,521	8,475	9,396	9,374	10,532	11,024	14,493	14,794	17,407
CWIP	1,237	1,400	1,342	—	2,429	2,938	4,496	2,739	3,266	3,009
Investments	246	312	360	—	591	997	543	372	252	1,051
	9,932	12,869	16,277	—	21,461	19,455	23,827	27,467	31,473	37,036
Total assets	16,249	21,101	26,454	—	33,854	33,922	39,890	45,072	49,785	58,502

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	55.5%	57.9%	60%	56.8%	54.6%	56.5%	58.9%	59.9%
EBITDA margin %	20.2%	20.9%	21.5%	18.7%	15%	20.2%	20.8%	20.3%
EBIT margin %	16.8%	16.7%	17.3%	13.9%	10%	14.9%	15.6%	15.1%
PAT margin %	12.1%	12.3%	21.5%	11.3%	7.8%	10.9%	11%	10.4%
Working capital
Receivable days	64	—	52	62	66	61	66	77
Inventory days	304	—	333	272	275	284	295	326
Payable days	1	—	103	97	125	129	117	151
NWC days	366	—	281	237	216	216	244	252
Leverage
Current ratio	1.28	—	1.85	2.21	1.87	1.95	1.85	1.81
Debt to EBITDA	1.71	—	0.93	0.54	1.31	1.08	1.21	1.12
Debt to equity	0.49	—	0.23	0.1	0.18	0.21	0.24	0.2
Interest coverage	13.1	24.7	62.5	73.6	19.7	16.8	12.1	14.5
Asset turnover	0.74	—	0.73	0.69	0.62	0.64	0.64	0.58
Return ratios
Return on assets %	8.9%	—	15.8%	7.8%	4.8%	7%	7%	6%
Return on capital employed %	25.6%	—	20.1%	14.6%	10.2%	15.9%	16.3%	14.7%
Return on equity %	17%	—	24.3%	10.8%	7.2%	10.6%	10.7%	9.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	51.83%	51.83%	51.83%	51.8%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	51.88%
	22.45%	20.72%	18.02%	16.73%	16.59%	16.29%	15.33%	14.37%	14.21%	13.94%	15.24%	16.38%
	18.29%	20.6%	23.28%	24.77%	25.13%	25.2%	26.23%	26.93%	27.6%	27.65%	25.82%	25.05%
	0%	0%	0%	0%	0%	0%	0%	0%	0%	0.03%	0.05%	0.05%
	7.43%	6.85%	6.87%	6.7%	6.46%	6.69%	6.62%	6.88%	6.37%	6.56%	7.07%	6.64%
No. of shareholders	—	—	—	—	—	—	—	—	2,47,662	2,36,859	2,41,298	2,39,073

Promoter holding up 0.05 percentage points since Sep 2023.

45 deals · 23 Sept 2021 – 16 Oct 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
16 Oct 2025	GOLDMAN SACHS BANK EUROPESE - ODI	Block	NSE	Buy	1,06,228	₹1,107.00	₹11.76 Cr
16 Oct 2025	GOLDMAN SACHS (SINGAPORE) PTE.- ODI	Block	NSE	Sell	1,06,228	₹1,107.00	₹11.76 Cr
25 Jan 2024	SOCIETE GENERALE	Block	BSE	Buy	14,84,323	₹1,160.10	₹172.20 Cr
25 Jan 2024	BNP PARIBAS ARBITRAGE	Block	BSE	Sell	14,84,323	₹1,160.10	₹172.20 Cr
25 Jan 2024	BNP PARIBAS ARBITRAGE	Block	BSE	Sell	1,50,001	₹1,160.10	₹17.40 Cr
25 Jan 2024	SOCIETE GENERALE	Block	NSE	Sell	1,07,558	₹1,160.10	₹12.48 Cr
25 Jan 2024	MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND	Block	BSE	Buy	1,06,480	₹1,160.10	₹12.35 Cr
25 Jan 2024	MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUND	Block	NSE	Buy	53,641	₹1,160.10	₹6.22 Cr
25 Jan 2024	MARSHALL WACE INVESTMENT STRATEGIES TOPS FUND	Block	NSE	Buy	44,921	₹1,160.10	₹5.21 Cr
25 Jan 2024	MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND	Block	BSE	Buy	27,571	₹1,160.10	₹3.20 Cr

1–10 of 45

1 / 5

Mr. Mangalam Ramasubramanian KumarNon-Executive - Independent Director-Chairperson
Mr. Nithyananda Reddy KambamExecutive Director-MD
Santhanam SubramanianChief Financial Officer
Mr. Madan Mohan Reddy MettuExecutive Director
Mr. Venkata Ramprasad Reddy PenakaNon-Executive - Non Independent Director
Mr. Sarath Chandra Reddy PenakaNon-Executive - Non Independent Director
Mr. Girish Paman VanvariNon-Executive - Independent Director
Mr. Santanu MukherjeeNon-Executive - Independent Director
Mr. Satakarni MakkapatiNon-Executive - Non Independent Director
Mrs. Punita Kumar SinhaNon-Executive - Independent Director
B Adi ReddyCompany Secretary & Compliance Officer

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

End of day 30 Sept 2026 · underlying ₹1,672.0 · volume and open interest in contracts

3

Expiry	Close	Chg	% Chg	Settlement	Open interest	Change in OI	Volume	Lot size
27 Oct 2026	₹1,676.9	-40.8	-2.4%	₹1,676.9	22,788	+579	2,606	550
23 Nov 2026	₹1,687.2	-40.1	-2.3%	₹1,687.2	81	+17	41	550
29 Dec 2026	₹1,722.9	0	0%	₹1,698.4	0	0	0	550

Open the chart icon on a row for that contract's close over 103 stored sessions, with open interest as bars beneath it.

11

27 Oct 2026 23 Nov 2026 29 Dec 2026

Calls				Strike	Puts
OI	Chg OI	Volume	LTP	—	LTP	Volume	Chg OI	OI
0	0	0	₹0.0	1,440

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

117

across 22 fund houses

Held by these funds

5.25%

of the company's equity

All mutual funds

16.71%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

117 schemes · 22 fund houses

		Shares
Large and Midcap Fund	SBI Mutual Fund	47 L	806.99	1.91%	0.809%	-6.57 L
Flexicap Fund	SBI Mutual Fund	40.08 L	688.15	2.96%	0.69%	-0
Midcap Fund	SBI Mutual Fund	30.39 L	521.71	2.13%	0.523%	-0
Contra Fund	SBI Mutual Fund	15.65 L	268.7	0.56%	0.269%	-0
Focused Fund	Old Bridge Mutual Fund	15.14 L	259.91	5.97%	0.261%	-0
ELSS Tax Saver Fund	SBI Mutual Fund	15 L	257.55	0.81%	0.258%	-0
Healthcare Opportunities Fund	SBI Mutual Fund	13.18 L	226.33	3.9%	0.227%	-1,808
Dividend Yield Fund	SBI Mutual Fund	12 L	206.04	2.41%	0.207%	-0

1–8 of 117

1 / 15

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

42 announcementsExport CSV

1 Oct 2026, 12:54 pmCompany Update

Announcement under Regulation 30 (LODR)-Acquisition

Acquisition PDF

30 Sept 2026, 9:28 pmCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

29 Sept 2026, 4:45 pmCompany Update

Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

General PDF

21 Sept 2026, 4:05 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

15 Sept 2026, 6:14 pmCompany Update

Completion Of US FDA Inspection At Unit-II Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company

General PDF

15 Sept 2026, 1:10 pmCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

12 Sept 2026, 12:50 pmCompany Update

Announcement under Regulation 30 (LODR)-Acquisition

Acquisition PDF

11 Sept 2026, 5:34 pmCompany Update

Completion Of US FDA Inspection At Unit-IV Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company

General PDF

Date	Category	Subject	Filing
1 Oct 2026, 12:54 pm	Company Update Acquisition	Announcement under Regulation 30 (LODR)-Acquisition	PDF
30 Sept 2026, 9:28 pm	Company Update Press Release / Media Release	Announcement under Regulation 30 (LODR)-Press Release / Media Release

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	55.5%	57.9%	60%	56.8%	54.6%	56.5%	58.9%	59.9%
EBITDA margin %	20.2%	20.9%	21.5%	18.7%	15%	20.2%	20.8%	20.3%
EBIT margin %	16.8%	16.7%	17.3%	13.9%	10%	14.9%	15.6%	15.1%
PAT margin %	12.1%	12.3%	21.5%	11.3%	7.8%	10.9%	11%	10.4%
Working capital
Receivable days	64	—	52	62	66	61	66	77
Inventory days	304	—	333	272	275	284	295	326
Payable days	1	—	103	97	125	129	117	151
NWC days	366	—	281	237	216	216	244	252
Leverage
Current ratio	1.28	—	1.85	2.21	1.87	1.95	1.85	1.81
Debt to EBITDA	1.71	—	0.93	0.54	1.31	1.08	1.21	1.12
Debt to equity	0.49	—	0.23	0.1	0.18	0.21	0.24	0.2
Interest coverage	13.1	24.7	62.5	73.6	19.7	16.8	12.1	14.5
Asset turnover	0.74	—	0.73	0.69	0.62	0.64	0.64	0.58
Return ratios
Return on assets %	8.9%	—	15.8%	7.8%	4.8%	7%	7%	6%
Return on capital employed %	25.6%	—	20.1%	14.6%	10.2%	15.9%	16.3%	14.7%
Return on equity %	17%	—	24.3%	10.8%	7.2%	10.6%	10.7%	9.2%

Calls	Strike	Puts
0	0	0	₹0.0	1,440

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	3,279	1,955	1,651	4,381	3,329	5,016	2,387	2,435	3,925	5,526
	-1,787	-1,927	-2,903	-1,568	599	-3,215	-3,978	-4,256	-1,875	-3,458
	-1,915	864	1,919	-1,947	-1,365	-2,969	1,814	800	120	-1,269
Net cash flow	-424	892	667	866	2,563	-1,168	223	-1,021	2,169	799
Free cash flow	3,279	1,955	1,651	4,381	1,891	2,964	-17	-346	1,957	2,841
CFO / Operating profit %	95.5%	51.8%	41.8%	90.8%	62.4%	114.4%	64.2%	41.7%	59.6%	80.7%

Aurobindo Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

3

11

Fund holders

Documents

Announcements

Events

Announcements

3

11

Announcements

Annual reports

Investor Presentation and earnings call

39

1

1

Compounded sales growth

Compounded profit growth

Return on equity

Aurobindo Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Futures3

Option chain11

Fund holders

Documents

Announcements

Events

Announcements

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Futures3

Option chain11

Announcements

Annual reports

Investor Presentation and earnings call

Dividends39

Board meetings1

Stock splits1

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

3

11

3

11

39

1

1